Financial Statements

Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV)

$2.54
0.05 (+2.01%)

Income Statement

Quarter Data

Balance Sheet Statement

Quarter Data
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Short-term debt -------6.6313.6214.20-
Other Assets 0.941.152.353.383.162.111.873.564.5615.770.11
Total current liabilities 8.1813.227.8217.6114.9115.928.4412.5018.4117.5614.49
Cash and cash equivalents 12.8552.6736.9225.7215.5114.6214.3412.569.555.2617.55
Long-term debt 2.7913.2621.9612.9023.1018.0416.6811.01--0.01
Cash and short-term investments 12.8552.6736.9225.7215.5114.6214.3412.569.555.2617.55
Total debt 5.5019.7124.4522.6931.3828.4118.4317.6413.6214.2011.19
Inventories 2.593.383.323.183.694.834.303.733.180.110.11
Deferred revenue 7,634.004,929.005.242.630.210.110.100.100.090.17-
Goodwill and Intangible Assets 4.564.334.113.9213.2713.2712.9512.3711.130.370.37
Total non-current liabilities 20.2330.2533.7719.1924.0228.5017.0511.120.201.217.58
Total non-current assets 6.657.408.199.2717.4817.0316.4515.8616.7514.343.40
Total liabilities 28.4143.4741.5936.8038.9344.4225.4923.6218.6118.7722.07
Total assets 24.7566.3551.5343.2542.0638.7237.7034.6131.6123.9923.23
Other comprehensive income ----0.260.701.001.261.391.22-
Short-term investments -----------
Property, Plant & Equipment Net 1.311.681.712.171.051.581.631.163.052.302.96
Net Debt -7.35-32.96-12.47-3.0315.8713.794.095.084.078.94-6.36
Investments 0.280.460.250.09---0.350.680.040.04
Total shareholders equity -3.6622.879.956.463.13-5.7012.2110.9913.005.221.16
Retained earnings (deficit) -182.50-210.00-242.45-274.73-300.91-338.27-357.02-379.06-401.75-414.38-425.27
Long-term investments 0.280.460.250.09-------
Receivables 1.862.202.494.044.261.361.311.240.140.181.31
Payables 1.150.600.271.580.97-1.01---0.33
Total current assets 18.1058.9543.3433.9824.5821.6921.2418.7514.869.6519.82

Cash Flow Statement

Quarter Data
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Operating Cash Flow -23.81-23.57-35.32-32.19-34.56-30.33-20.47-19.53-18.13-11.97-5.91
Free Cash Flow -24.03-24.18-35.88-33.39-35.08-31.35-21.09-19.60-19.62-12.11-5.97
Capital Expenditure -0.22-0.61-0.56-1.20-0.52-1.02-0.62-0.07-1.50-0.13-0.07
Depreciation & Amortization 1.680.930.860.931.630.781.091.182.152.000.90
Acquisitions and disposals -----------
Deferred income taxes -----------
Investment purchases -----------
Accounts payables 413.00811.00-1.441.18-0.41-1.151.04-0.67-1.82-1.53-0.03
Sales/Maturities of investments -----------
Change in working capital -6.31-1.38-8.45-5.99-7.53-0.01-6.37-0.77-1.04-1.03-0.94
Debt repayment ---4.53-2.69-22.30-1.96-25.03--4.72--3.69
Other non-cash items 4.044.374.725.14-2.496.263.552.103.44-0.315.02
Investing Cash Flow -0.22-1.29-0.56-1.203.69-1.34-0.610.06-1.38-0.135.57
Cash at beginning of period 12.6112.8552.6736.9225.7215.5114.6214.3412.569.555.26
Stock-based compensation 2,649.003,055.003.323.903.613.102.041.080.750.350.13
Net cash flow / Change in cash 0.2439.81-15.75-11.21-10.21-0.88-0.28-1.78-2.69-4.9212.29
Effect of forex changes on cash -----0.11-0.09-0.080.010.02-0.00
Financing Cash Flow 24.2764.6820.1422.1920.7730.8720.8017.6116.827.1712.63
Dividend payments -------0.07----
Accounts receivables -986.00-902.00-0.67-1.81-1.212.060.33-0.181.13-0.17-1.20
Cash at end of period 12.8552.6636.9225.7115.5114.6314.3412.569.884.6317.55
Net cash provided by operating activities -23.81-23.57-35.32-32.19-34.56-30.33-20.47-19.53-18.13-11.97-5.91
Other working capital 9,915.0045,730.0035.5216.379.675.7712.816.25-3.55-7.915.34
Inventory -446.00-777.000.060.14-0.46-0.810.490.470.250.470.26

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) -162-183-210-242-275-301-338-357-379-402-414
Net Income -23-27-32-32-26-37-19-22-23-13-11
Stock Dividends 3-0---00----
Dividend Paid -------0----
Retained Earnings -183-210-242-275-301-338-357-379-402-414-425

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE 31222122132
Annual Depreciation -1112-121-03-11
Capital Expenditure -0-1-1-1-1-1-1-0-1-0-0
Net PPE 12221221323

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) 5544413131312110
New Purchases -----------
Intangible and Goodwill 5444131313121100

Plus Therapeutics Inc income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Plus Therapeutics Inc FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.